Across TCGA pan-cancer cohorts, IGLV2-14 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGLV2-14 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IGLV2-14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV2-14 expression acts as an unfavorable survival marker.
STAD, COAD, and LIHC are the cancer types where IGLV2-14 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.